Patient-reported outcomes in randomised controlled trials of prostate cancer: Methodological quality and impact on clinical decision making

European Urology

Volumn 66, Issue 3, 2014, Pages 416-427

  Efficace, Fabio ^a   Feuerstein, Michael ^b   Fayers, Peter ^c   Cafaro, Valentina ^a   Eastham, James ^b   Pusic, Andrea ^b   Blazeby, Jane ^d  

^a GIMEMA Data Center   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Clinical decision making; Clinical trials; Patient reported outcomes; Prostate cancer; Quality of life

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; HUMAN; INTERNAL VALIDITY; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); DECISION MAKING; MALE; MANAGEMENT; METHODOLOGY; PROSTATIC NEOPLASMS; STANDARDS;

DECISION MAKING; HUMANS; MALE; PATIENT OUTCOME ASSESSMENT; POLICY MAKING; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84905922960     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.10.017     Document Type: Review

References (40)

1. P. Boyle, and B. Levin World Health Organization. World Cancer Report 2008 IARC Press Lyon, France
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
3. A.M. Wolf, R.C. Wender, R.B. Etzioni American Cancer Society Prostate Cancer Advisory Committee American Cancer Society guideline for the early detection of prostate cancer: update 2010 CA Cancer J Clin 60 2010 70 98
4. J. Singh, E.J. Trabulsi, and L.G. Gomella The quality-of-life impact of prostate cancer treatments Curr Urol Rep 11 2010 139 146
5. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Updated December 2009.
6. J. Lipscomb, B.B. Reeve, and S.B. Clauser et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward J Clin Oncol 25 2007 5133 5140
7. F. Efficace, A. Bottomley, and G. van Andel Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials Cancer 97 2003 377 388
8. D. Osoba, I.F. Tannock, D.S. Ernst, and A.J. Neville Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone J Clin Oncol 17 1999 1654 1663
9. I.F. Tannock, D. Osoba, and M.R. Stockler et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
10. J.R. Johnson, G. Williams, and R. Pazdur End points and United States Food and Drug Administration approval of oncology drugs J Clin Oncol 21 2003 1404 1411
11. F. Efficace, A. Bottomley, and D. Osoba et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21 2003 3502 3511
12. E. Basch, A.P. Abernethy, and C.D. Mullins et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology J Clin Oncol 30 2012 4249 4255
13. E. Basch Toward patient-centered drug development in oncology N Engl J Med 369 2013 397 400
14. M. Brundage, B. Bass, and J. Davidson et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers Qual Life Res 20 2011 653 664
15. F. Efficace, A. Bottomley, V. Vanvoorden, and J.M. Blazeby Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials Eur J Cancer 40 2004 187 197
16. A. Bottomley, F. Efficace, and R. Thomas et al. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials J Clin Oncol 21 2003 2982 2992
17. Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI) Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective JAMA 307 2012 1636 1640
18. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
19. M. Brundage, J. Blazeby, and D. Revicki et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards Qual Life Res 22 2013 1161 1175
20. J.P. Higgins, D.G. Altman, P.C. Gøtzsche Cochrane Bias Methods Group; Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
21. M. Staquet, R. Berzon, D. Osoba, and D. Machin Guidelines for reporting results of quality of life assessments in clinical trials Qual Life Res 5 1996 496 502
22. C.W. Lee, and K.N. Chi The standard of reporting of health-related quality of life in clinical cancer trials J Clin Epidemiol 53 2000 451 458
23. M. Calvert, J. Blazeby, D.G. Altman, D.A. Revicki, D. Moher, M.D. Brundage CONSORT PRO Group Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension JAMA 309 2013 814 822
24. A.K. Kvam, P. Fayers, M. Hjermstad, N. Gulbrandsen, and F. Wisloff Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations Eur J Haematol 83 2009 279 289
25. C.M. Moinpour, K.A. Hayden, J.M. Unger Southwest Oncology Group Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy J Clin Oncol 26 2008 112 120
26. I.F. Tannock, R. de Wit, W.R. Berry TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
27. D.P. Petrylak, C.M. Tangen, and M.H. Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
28. A.J. Armstrong, E. Garrett-Mayer, and Y.C. Ou Yang et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 2007 3965 3970
29. D.R. Berthold, G.R. Pond, R. de Wit, M. Eisenberger, I.F. Tannock TAX 327 Investigators Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann Oncol 19 2008 1749 1753
30. D.R. Berthold, G.R. Pond, M. Roessner, R. de Wit, M. Eisenberger, A.I. Tannock TAX-327 Investigators Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study Clin Cancer Res 14 2008 2763 2767
31. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
32. Southwest Oncology Group D.L. Berry, and C.M. Moinpour et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone J Clin Oncol 24 2006 2828 2835
33. P. Warde, M. Mason, K. Ding NCIC CTG PR.3/MRC UK PR07 investigators Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111
34. P. Fransson, J.A. Lund, J.E. Damber Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3 Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial Lancet Oncol 10 2009 370 380
35. I.M. Thompson Jr., C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 2006 2329 2335
36. P. Fayers, and R. Hays Assessing quality of life in clinical trials 2005 Oxford University Press New York, NY
37. D.L. Fairclough, H.F. Peterson, and V. Chang Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat Med 17 1998 667 677
38. C.S. Cleeland Symptom burden: multiple symptoms and their impact as patient-reported outcomes J Natl Cancer Inst Monogr 2007 16 21
39. D. Moher, B. Pham, and T.P. Klassen et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 53 2000 964 972
40. P. Jüni, F. Holenstein, J. Sterne, C. Bartlett, and M. Egger Direction and impact of language bias in meta-analyses of controlled trials: empirical study Int J Epidemiol 31 2002 115 123